NEW YORK, July 9, 2018 — King & Spalding today announced that intellectual property lawyers Gerald Flattmann and Evan Diamond have joined the firm as partners in its Trial and Global Disputes practice group in the New York office. They have extensive experience with biotechnology and pharmaceuticals patent litigation. Flattmann will serve as the firm’s Global Chair of Life Sciences Patent Litigation.
“Gerald and Evan are first-chair patent trial lawyers who have been involved in a number of significant Hatch-Waxman disputes,” said Andy Bayman, head of King & Spalding’s Trial & Global Disputes practice group. “Their capabilities in the pharma space dovetail well with the firm’s focus on clients in the Life Sciences sector and they add to the firm’s deep trial bench.”
Kenny Steinthal, leader of King & Spalding’s intellectual property team, added “Gerald and Evan have substantial experience litigating high-stakes patent disputes in federal district courts and before the Patent Trial and Appeal Board of the U.S. Patent Office. Bringing them on board enhances our ability to be a firm of choice for companies protecting high-stakes branded products.”
Both new partners join King & Spalding from Paul Hastings.
Flattmann’s practice focuses on all aspects of patent litigation, licensing and counseling. He counsels biotechnology and pharmaceutical companies on how to protect their patent portfolios. Flattmann speaks regularly on topics relating to patent litigation and intellectual property. He has been recognized as a leading patent lawyer by Chambers USA; The Legal 500; and Managing Intellectual Property IP Stars (2013). Flattmann received his B.S. from Yale University and his J.D. from Harvard Law School.
Diamond likewise focuses his practice on patent litigation matters, particularly in the fields of pharmaceuticals and biotechnology. He has led a number of trial teams that have obtained favorable judgments and settlements for branded pharmaceutical clients in Hatch-Waxman litigations and inter partes review proceedings. Diamond received his B.A., summa cum laude, and his M.S. from the University of Pennsylvania and his J.D., cum laude, from Harvard Law School.
“King & Spalding has a renowned reputation in the pharmaceutical, medical devices and life sciences sectors,” said Flattmann. “We look forward to working with our new colleagues across their global network to help clients develop strong patent strategies so they can navigate the challenges and complexities that arise from litigation.”
Five partners and five counsel have joined King & Spalding’s New York office in the last month. Flattmann and Diamond join real estate finance partners Erik Andersen, Elizabeth Gable and Jared Zaben who began at the firm at the beginning of June. Intellectual property litigators Tom Friel and Jim Brogan joined the firm’s Silicon Valley office and Lori Gordon joined the firm’s Washington DC office earlier this year.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,000 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.